drugset
drugset / Trial / NCT03696550

A Safety and PK Study of IV Eravacycline

NCT03696550 ↗

Phase 1 Completed 19 enrolled Tetraphase Pharmaceuticals, Inc
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase 1, open-label, multi-center study to determine the pharmacokinetics and safety of intravenous Eravacycline in Children with Suspected or Confirmed Bacterial Infection. Male and Female subjects from 8 to \<18 years of age who fulfill the inclusion/exclusion criteria will be enrolled in this study.

Timeline

Start
2018-12-20
Primary completion
2021-03-14
Completion
2021-03-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Eravacycline Small molecule 1.5 mg/kg Intravenous
Subject Eravacycline Small molecule 1.75 mg/kg Intravenous

Indications

bacterial infectious disease